Sign in

    Micheal Almisry Sonntag

    Research Analyst at Leerink Partners

    Michael Almisry Sonntag is an analyst at Leerink Partners LLC, specializing in healthcare and life sciences research. He covers leading healthcare companies, leveraging a data-driven approach to provide timely and high-conviction investment recommendations, although specific platform performance metrics such as TipRanks success rate and average returns are not publicly available. Sonntag began his career as a registered broker and joined Leerink Partners in recent years, with a verified history and credentials listed on FINRA BrokerCheck. He holds FINRA securities licenses and maintains a clean professional record with focus on providing actionable insights for institutional clients.

    Micheal Almisry Sonntag's questions to AbCellera Biologics (ABCL) leadership

    Micheal Almisry Sonntag's questions to AbCellera Biologics (ABCL) leadership • Q4 2024

    Question

    Micheal Almisry Sonntag from Leerink Partners inquired about the drivers behind initiating new internal programs, particularly the focus on ion channels and GPCRs, and whether program initiation activity in 2025 would be similar to 2024.

    Answer

    CEO Carl L. Hansen outlined their program selection framework, which prioritizes high conviction in the science, large unmet need, differentiation, and a clear, efficient development path. He explained the focus on ion channels and GPCRs is due to many validated targets in these classes where an antibody can offer differentiation. He noted this is an area of competitive strength for AbCellera, representing about 50% of the pipeline, a proportion he expects to remain roughly constant.

    Ask Fintool Equity Research AI